Last reviewed · How we verify

azithromycin, sulphadoxine pyrimethamine, LLIN

University of Melbourne · Phase 3 active Small molecule

azithromycin, sulphadoxine pyrimethamine, LLIN is a Antimalarial combination therapy Small molecule drug developed by University of Melbourne. It is currently in Phase 3 development for Malaria prevention and treatment in endemic regions, Intermittent preventive treatment in pregnancy (IPTp) or infants (IPTi). Also known as: Zithromax, sulfadoxine-pyrimethamine.

This combination uses azithromycin (antibiotic), sulphadoxine-pyrimethamine (antimalarial), and long-lasting insecticidal nets (LLIN) to prevent and treat malaria through multiple mechanisms including parasite inhibition and mosquito vector control.

This combination uses azithromycin (antibiotic), sulphadoxine-pyrimethamine (antimalarial), and long-lasting insecticidal nets (LLIN) to prevent and treat malaria through multiple mechanisms including parasite inhibition and mosquito vector control. Used for Malaria prevention and treatment in endemic regions, Intermittent preventive treatment in pregnancy (IPTp) or infants (IPTi).

At a glance

Generic nameazithromycin, sulphadoxine pyrimethamine, LLIN
Also known asZithromax, sulfadoxine-pyrimethamine
SponsorUniversity of Melbourne
Drug classAntimalarial combination therapy
TargetPlasmodium falciparum dihydrofolate reductase (sulphadoxine-pyrimethamine); bacterial/parasite ribosome (azithromycin)
ModalitySmall molecule
Therapeutic areaInfectious Disease / Parasitology
PhasePhase 3

Mechanism of action

Azithromycin is a macrolide antibiotic with antimalarial properties that inhibits parasite protein synthesis. Sulphadoxine-pyrimethamine is a fixed-dose antimalarial combination that inhibits folate metabolism in Plasmodium parasites. LLINs provide physical and chemical barrier protection against mosquito vectors. Together, this combination addresses malaria through chemoprophylaxis and vector control.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about azithromycin, sulphadoxine pyrimethamine, LLIN

What is azithromycin, sulphadoxine pyrimethamine, LLIN?

azithromycin, sulphadoxine pyrimethamine, LLIN is a Antimalarial combination therapy drug developed by University of Melbourne, indicated for Malaria prevention and treatment in endemic regions, Intermittent preventive treatment in pregnancy (IPTp) or infants (IPTi).

How does azithromycin, sulphadoxine pyrimethamine, LLIN work?

This combination uses azithromycin (antibiotic), sulphadoxine-pyrimethamine (antimalarial), and long-lasting insecticidal nets (LLIN) to prevent and treat malaria through multiple mechanisms including parasite inhibition and mosquito vector control.

What is azithromycin, sulphadoxine pyrimethamine, LLIN used for?

azithromycin, sulphadoxine pyrimethamine, LLIN is indicated for Malaria prevention and treatment in endemic regions, Intermittent preventive treatment in pregnancy (IPTp) or infants (IPTi).

Who makes azithromycin, sulphadoxine pyrimethamine, LLIN?

azithromycin, sulphadoxine pyrimethamine, LLIN is developed by University of Melbourne (see full University of Melbourne pipeline at /company/university-of-melbourne).

Is azithromycin, sulphadoxine pyrimethamine, LLIN also known as anything else?

azithromycin, sulphadoxine pyrimethamine, LLIN is also known as Zithromax, sulfadoxine-pyrimethamine.

What drug class is azithromycin, sulphadoxine pyrimethamine, LLIN in?

azithromycin, sulphadoxine pyrimethamine, LLIN belongs to the Antimalarial combination therapy class. See all Antimalarial combination therapy drugs at /class/antimalarial-combination-therapy.

What development phase is azithromycin, sulphadoxine pyrimethamine, LLIN in?

azithromycin, sulphadoxine pyrimethamine, LLIN is in Phase 3.

What are the side effects of azithromycin, sulphadoxine pyrimethamine, LLIN?

Common side effects of azithromycin, sulphadoxine pyrimethamine, LLIN include Gastrointestinal disturbance (nausea, diarrhea), Rash, Headache, Allergic reactions (sulphonamide sensitivity).

What does azithromycin, sulphadoxine pyrimethamine, LLIN target?

azithromycin, sulphadoxine pyrimethamine, LLIN targets Plasmodium falciparum dihydrofolate reductase (sulphadoxine-pyrimethamine); bacterial/parasite ribosome (azithromycin) and is a Antimalarial combination therapy.

Related